IN2014MN01381A - - Google Patents

Info

Publication number
IN2014MN01381A
IN2014MN01381A IN1381MUN2014A IN2014MN01381A IN 2014MN01381 A IN2014MN01381 A IN 2014MN01381A IN 1381MUN2014 A IN1381MUN2014 A IN 1381MUN2014A IN 2014MN01381 A IN2014MN01381 A IN 2014MN01381A
Authority
IN
India
Prior art keywords
formulations
novel method
dry
biomolecules
reconstitution
Prior art date
Application number
Other languages
English (en)
Inventor
Jan Vos
Andrew John Macleod
Original Assignee
Xstalbio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xstalbio Ltd filed Critical Xstalbio Ltd
Publication of IN2014MN01381A publication Critical patent/IN2014MN01381A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Degasification And Air Bubble Elimination (AREA)
  • Mixers With Rotating Receptacles And Mixers With Vibration Mechanisms (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
IN1381MUN2014 2011-12-23 2012-12-24 IN2014MN01381A (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1122430.0A GB201122430D0 (en) 2011-12-23 2011-12-23 Reconstitution method for high concentration dry protein formulation
PCT/GB2012/053266 WO2013093525A1 (en) 2011-12-23 2012-12-24 Reconstitution method for high concentration dry protein formulations

Publications (1)

Publication Number Publication Date
IN2014MN01381A true IN2014MN01381A (enrdf_load_stackoverflow) 2015-04-17

Family

ID=45695059

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1381MUN2014 IN2014MN01381A (enrdf_load_stackoverflow) 2011-12-23 2012-12-24

Country Status (8)

Country Link
US (1) US20140308293A1 (enrdf_load_stackoverflow)
EP (1) EP2793852A1 (enrdf_load_stackoverflow)
JP (1) JP2015511129A (enrdf_load_stackoverflow)
BR (1) BR112014015605A2 (enrdf_load_stackoverflow)
CA (1) CA2859287A1 (enrdf_load_stackoverflow)
GB (1) GB201122430D0 (enrdf_load_stackoverflow)
IN (1) IN2014MN01381A (enrdf_load_stackoverflow)
WO (1) WO2013093525A1 (enrdf_load_stackoverflow)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201313368D0 (en) 2013-07-26 2013-09-11 Xstalbio Ltd Novel Reconstitution devices
US20170274012A1 (en) * 2014-09-03 2017-09-28 Entegrion, Inc. Acceleration of Reconstitution of Plasma Powder by Mixing with Small Beads
US10143625B2 (en) 2015-03-17 2018-12-04 Recon Therapeutics, Inc. Pharmaceutical reconstitution
WO2018033482A1 (en) * 2016-08-17 2018-02-22 Boehringer Ingelheim International Gmbh Process for the preparation of highly concentrated liquid formulations containing biomolecules

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178884A (en) * 1988-05-18 1993-01-12 Cryopharm Corporation Lyophilized and reconstituted red blood cell compositions
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen
DE10211227A1 (de) * 2002-03-13 2003-10-02 Aventis Behring Gmbh Verfahren zur Rekonstitution von Iyophilisierten Proteinen
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
EP1958618A1 (de) * 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
WO2011017070A1 (en) 2009-07-28 2011-02-10 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations

Also Published As

Publication number Publication date
US20140308293A1 (en) 2014-10-16
WO2013093525A1 (en) 2013-06-27
CA2859287A1 (en) 2013-06-27
BR112014015605A2 (pt) 2017-07-04
JP2015511129A (ja) 2015-04-16
GB201122430D0 (en) 2012-02-08
EP2793852A1 (en) 2014-10-29

Similar Documents

Publication Publication Date Title
IL254879B (en) History of dolastatin associated with unnatural amino acids and pharmaceutical preparations containing them
EP2908818A4 (en) CONJUGATES OF DRUG DELIVERY CONTAINING ARTIFICIAL AMINO ACIDS AND METHODS OF USE
AR093377A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
IL222120A (en) Annals (indole-1-yl) -carbonylalkyl, process for preparation, pharmaceutical preparations containing them and their use in the preparation of cancer drugs
RS55739B1 (sr) Novi derivati indolizina, postupak njihove proizvodnje i farmaceutske kompozicije koje ih sadrže za lečenje kancera
MX338515B (es) Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio.
PL3222952T3 (pl) Sposób i układ liofilizacji kompozycji do wstrzykiwania, zwłaszcza kompozycji farmaceutycznych
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
IL230874A (en) History of dihydroquinoline-2-on-egg scallops, their preparation process, pharmaceutical preparations containing them and their use in the preparation of drugs
IL223795A (en) History of Tetrahydro-Pyrido-Pyrimidine
MX2015000337A (es) Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles.
IL240496B (en) History of pyridine, process for their preparation, pharmaceutical preparations containing them and their use in medicine
NZ708016A (en) Lyophilized preparations of melphalan flufenamide
PL2760878T3 (pl) Pochodne estra-1,3,5(10),16-tetraeno-3-karboksyamidowe, sposób ich wytwarzania, preparaty farmaceutyczne, które je zawierają, i ich zastosowanie do wytwarzania leków
IL226205B (en) Fusion proteins, pharmaceutical preparations containing them and their use in the preparation of drugs for the treatment of cancer
LT2717914T (lt) Sulėtinto atpalaidavimo kompozicijos, skirtos baltymų pateikimui į akį, ir jų paruošimo būdai
TN2015000007A1 (en) 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
IL231050A0 (en) Pyridines are converted in 4,5,6,7 tetrahydro-1hydrogen-pyrazolo[3,4-si], their use as medicine and medical preparations containing them
IL241540A (en) Preparations containing digestive enzymes and nutrients suitable for internal insertion
MX2013013649A (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
PL2911524T3 (pl) Sposób wytwarzania kompozycji białkowych o słabej rozpuszczalności, otrzymane kompozycje i ich zastosowanie w produktach wypieku pieczywa
IN2014MN01381A (enrdf_load_stackoverflow)
IL222780A0 (en) Pharmaceutical compositions comprising paracetamol and process for preparing the same
MX355719B (es) Composicion farmaceutica en forma de una suspension oral que comprende una fraccion flavonoica y goma de xantano.
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.